The NASDAQ NeuroInsights Neurotech Index (NERV) underwent its biannual assessment resulting in the addition of three companies Adolor (ADLR), Noven (NOVN) and Somanetics (SMTS) and the loss of seven whose market cap dropped below the $200 million minimum, namely Alexza (ALXA), Aspect Medical (ASPM), Javelin (JAV), Micrus (MEND), Neurocrine (NBIX), Northstar Neuroscience (NSTR), and Vanda Pharmaceuticals (VNDA). Realtime quote of NERV.

Index Performance: As of June 30, historical back-testing indicates that ^NERV is up 9% from a theoretical start date of June 2005, compared to respective gains of 7.5% and 17% for the S&P 500 and the NASDAQ Biotech Index. The historical values prior to the Index launch are based on NASDAQ’s calculation of how the index may have performed over time if it existed. The back-tested Index Values are purely hypothetical and are solely for information purposes only. Back-tested Index Values do not represent actual Index performance and are not indicative of actual Index performance. The index began calculation on September 25, 2007.